Clinical Governance

What this covers

Clinical governance is the structure that keeps a healthcare operator answerable for the care it delivers. In regulated industries — medicinal cannabis, telehealth, aesthetic medicine, digital health — governance is increasingly the difference between a sustainable platform and one that finds itself in front of AHPRA, the TGA, or the press. I design and operate governance systems that are practical for the business and defensible to the regulator, drawing on direct experience as a treating clinician and as a founder of a clinician-led telehealth service.

Who it is for

• Telehealth platforms scaling beyond founder-level clinical oversight.
• Medicinal cannabis operators reviewing their model in light of the AHPRA December 2024 position statement and tightening state RTPM frameworks.
• Aesthetic medicine groups operating under the NSW Health Ministerial Statement on cosmetic procedures and equivalent state reforms.
• Health-tech companies whose products make clinical recommendations and need a credible governance owner before regulators ask who is.

Typical deliverables

• Clinical governance committee design, charter, and chair (where appropriate).
• Incident review, open disclosure, and morbidity-and-mortality processes.
• Practitioner credentialing, scope-of-practice, and supervision frameworks.
• Drift, override, and outcome monitoring for AI-assisted clinical tools.
• Patient feedback, complaint, and Notification triage pathways.
• Pre-investment or pre-acquisition clinical governance due diligence.

Why Dr Rob

Active treating clinician across telehealth, cosmetic medicine, and medicinal cannabis. Founder of Claims Doctor, a same-day WorkCover and CTP telehealth service operating under AHPRA, TGA, and state-based real-time prescription monitoring frameworks. Public writing on AI clinical governance and clinician-led product design at rob.doctor/blog. Comfortable with the primary regulatory instruments — including the WA Monitored Medicines Prescribing Code Part 4 (12 December 2024), AHPRA's December 2024 medicinal cannabis position statement, the TGA Special Access Scheme guidelines, and state-by-state RTPM rulebooks — rather than secondary commentary.